MURPHY CANYON ACQUISITION Stock Price, News & Analysis

Murphy Canyon Acquisition Corp. (Nasdaq: MURF), a special purpose acquisition company, is poised to complete a business combination with Conduit Pharmaceuticals Limited, forming Conduit Pharmaceuticals Inc. The company focuses on providing an efficient model for compound development, aiming to acquire Phase II-ready assets for clinical trials and possible third-party license deals. Led by Dr. David Tapolczay and Dr. Freda Lewis-Hall, Conduit boasts a team of experienced pharmaceutical executives. The completion of the Business Combination is anticipated soon, subject to specified conditions.

As part of the transaction, Murphy Canyon Acquisition Corp., with Jack Heilbron as CEO and Chairman, will transition its stock symbols from "MURF" to "CDT" for common stock and from "MURFW" to "CDTTW" for public warrants on The Nasdaq Global Market. Murphy Canyon is sponsored by Murphy Canyon Acquisition Sponsor, LLC, a subsidiary of Presidio Property Trust, Inc.